Trial Profile

Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Memory cytokine enriched natural killer cell therapy-ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary)
Indications Advanced breast cancer; Colon cancer; Duodenal neoplasms; Male breast cancer; Osteosarcoma; Pancreatic cancer; Rectal cancer; Renal cancer; Solid tumours
Focus Adverse reactions; First in man; Proof of concept
Acronyms QUILT 3.076
Sponsors ImmunityBio

Most Recent Events

11 Dec 2025 Planned End Date changed from 31 May 2025 to 31 May 2026.
11 Dec 2025 Planned primary completion date changed from 31 May 2025 to 31 May 2026.
02 Jun 2025 According to an ImmunityBio media release, data from this study presented at the 2025 ASCO Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com